Clinical trials: Primary
Hereditary Angioedema (HAE)
Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)
The purpose of this study is to evaluate the efficacy and safety of DX-88 (ecallantide) versus placebo in the treatment of moderate to severe acute attacks of hereditary angioedema.
- Trial name
- NCT00457015
- Testing
- ecallantide, Phosphate Buffer Saline (PBS), pH 7.0
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 96 people
- Sponsor
- Shire
Non-small Cell Lung Cancer
Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy
This is a phase I/II study in Japan to evaluate the safety of EMD531444 and its effects on survival time in patients with stage III unresectable non-small cell lung cancer.
- Trial name
- NCT00960115
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Saline
- Where
- Germany
- Volunteers
- 178 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Depressive Disorders, Alcohol Use Disorders
Implementing a Blended Care Model That Integrates Mental Healthcare and Primary Care Using Telemedicine and Care Management for Patients With Depression or Alcohol Use Disorder in Small Primary Care Clinics
Integrating mental health treatments into the primary care delivered at Community Based Outpatient Clinics(CBOCs) that are geographically accessible to rural Veterans is a major priority for the Department of Veterans Affairs.
- Conditions
- Depressive Disorders, Alcohol Use Disorders, Post-traumatic Stress Disorder (PTSD)
- Trial name
- Tele-PCMHI (NCT02713217)
- Testing
- Usual Care, Blended Telemedicine-Based Integrated Care
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- VA Office of Research and Development
Pterygium
Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24) Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup (n=51)
- Trial name
- Pterygium (NCT03049852)
- Testing
- CBT-001 single dose, Vehicle, CBT-001 Multi-dose
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Cloudbreak Therapeutics, LLC
Pancreatic Cancer, Pancreas Cancer
Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies
In light of this new technology and preliminary findings of low toxicity of online, adaptive, magnetic resonance (M)-guided stereotactic radiation on a single arm prospective study, the investigators propose to compare this…
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas, Hepatocellular Carcinoma
- Trial name
- NCT02950025
- Testing
- Online, adaptive MR-guided SBRT, Online, non-adaptive MR-guided SBRT, European Organization for Research and Treatment of Cancer (EORTC) QLQ-30
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Drug Use Disorders, Illicit Drug Use
Digital Treatments for Opioids and Other Substance Use Disorders in Primary Care
The DIGITS Trial addresses a critical knowledge gap: How to best implement digital treatments for opioids and other substance use disorders in primary care.
- Conditions
- Drug Use Disorders, Illicit Drug Use, Alcohol-Related Disorders, Opioid Use Disorder
- Trial name
- DIGITS (NCT05160233)
- Testing
- Standard implementation, Health Coaching, Practice Facilitation
- Where
- United States
- Volunteers
- 18,430 people
- Sponsor
- Kaiser Permanente
Ovarian Cancer
Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
The purpose of this study is to find out if the combination of Paclitaxel once per week with Pembrolizumab once every 3 weeks will help participants with this disease.
- Trial name
- NCT02440425
- Testing
- Pembrolizumab, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Opioid-Related Disorders
Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings
Treating Opioid Patients' Pain and Sadness (TOPPS) focuses on the relationship of pain, depression, opioid and other substance misuse, and functioning.
- Trial name
- TOPPS (NCT03698669)
- Testing
- Treating Opioid Patients' Pain and Sadness (TOPPS), Health Education (HE)
- Where
- 2 sites in United States
- Volunteers
- 163 people
- Sponsor
- Boston University
Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia
Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
This phase II trial studies how well nivolumab works in treating patients with primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.
- Conditions
- Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
- Trial name
- NCT02421354
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Hyperoxaluria, Primary Hyperoxaluria Type 1
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.
- Conditions
- Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3
- Trial name
- PHYOX8 (NCT05001269)
- Testing
- nedosiran
- Where
- 13 sites in United States, Canada and 9 more
- Volunteers
- 27 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Osteoarthritis, Knee
Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis
Matrix metalloproteinases (MMPs) have been implicated in the cartilage degradation. PG-530742 inhibits some MMPs, potentially limiting cartilage degradation and disease progression.
- Trial name
- NCT00041756
- Testing
- PG-530742, 50 mg PG-530742, 100 mg PG-530742
- Where
- 23 sites in Hungary, United Kingdom
- Volunteers
- 395 people
- Sponsor
- Procter and Gamble
Pulmonary Fibrosis
Supplemental Oxygen in Pulmonary Fibrosis
To enhance understanding of supplemental oxygen-its utility in and adoption by patients with pulmonary fibrosis-by examining how patients perceive it and by determining how perceptions and patient-centered outcome measures change…
- Trial name
- NCT01961362
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Primary Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
This is an open-label, single-armed, prospective single-centre clinical study to evaluate the effect of riociguat on right heart size and function in patients with manifest PAH and CTEPH.
- Trial name
- RIVERII (NCT04954742)
- Testing
- Riociguat
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Heidelberg University
Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
This phase II trial is to see if combining bevacizumab with low-dose cyclophosphamide works in treating patients with ovarian epithelial or primary peritoneal cancer that has come back or spread to other parts of the body.
- Conditions
- Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage IV Ovarian Cancer
- Trial name
- NCT00072566
- Testing
- Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
- Trial name
- NCT03704467
- Testing
- M6620, Avelumab, Carboplatin
- Where
- 13 sites in United States, Belgium and 1 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Haemophilus Influenzae Type b, Neisseria Meningitidis
Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
This study evaluates the immunogenicity and consistency of 3 Hib-MenCY-TT vaccine lots and the safety and immunogenicity of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine, when each are…
- Trial name
- NCT00289783
- Testing
- GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB
- Where
- 93 sites in United States, Australia and 1 more
- Volunteers
- 4,441 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Recurrent Ovarian Cancer, Fallopian Tube Cancer
A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers
The primary objective of this study is to investigate the feasibility, tolerability and safety of surgical debulking and resection with heated intraoperative chemotherapy (HIPEC) followed by repeated intraperitoneal chemotherapy…
- Trial name
- HIPEC (NCT01659554)
- Testing
- Cisplatin, Doxorubicin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
Sleep Disorders
Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
The purpose of this study is to establish the efficacy and safety of Circadin in children with neurodevelopmental disorders and to determine the dose, this randomized, placebo-controlled study is planned to evaluate the efficacy…
- Trial name
- NCT01906866
- Testing
- Circadin 2/5/10 mg
- Where
- 28 sites in United States, Finland and 3 more
- Volunteers
- 125 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
RATIONALE: Giving chemotherapy drugs, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells and prepares the patient's…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis
- Trial name
- NCT00309842
- Testing
- filgrastim, cyclophosphamide, cyclosporine
- Where
- 2 sites in United States
- Volunteers
- 213 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Panic Disorder
Using the Canary Breathing System for Panic Disorder Patients
The purpose of this study is to test the effectiveness of the Canary Breathing System (CBS) in treating the symptoms of panic disorder.
- Trial name
- NCT01955954
- Testing
- Canary Breathing System
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Palo Alto Health Sciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.